Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation

R. H. Wiesner, E. Marin, M. K. Porayko, J. L. Steers, R. A F Krom, C. V. Paya

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

CMV is one of the most frequent viral infections after orthotopic liver transplantation. Thus, there should be a high index of clinical suspicion, particularly in liver transplant recipients who have risk factors for the development of CMV disease, including donor CMV seropositivity, the use of antilymphocyte preparations, and retransplantation. The availability of effective antiviral therapy to treat CMV disease has emphasized the importance of an aggressive approach to the early diagnosis and treatment of this viral infection. Ganciclovir has been a major advancement in the treatment of severe CMV disease and has had a major impact on reducing the incidence and severity of CMV disease and its complications in the liver transplant recipient. Furthermore, these antiviral agents are now being evaluated for their prophylactic potential. Indeed, a number of these agents or combinations of these agents have been shown to be effective in reducing the incidence and severity of CMV disease, particularly in the CMV-seropositive transplant recipient; however, the cost-effectiveness of such therapy and its overall impact on long-term graft and patient outcome remain poorly defined at this time. Further investigations will be needed to define the role and importance of prophylactic therapy for the prevention of CMV infection and disease in the liver transplant recipient.

Original languageEnglish (US)
Pages (from-to)351-366
Number of pages16
JournalGastroenterology Clinics of North America
Volume22
Issue number2
StatePublished - 1993

Fingerprint

Cytomegalovirus Infections
Liver Transplantation
Virus Diseases
Antiviral Agents
Therapeutics
Ganciclovir
Liver
Incidence
Cost-Benefit Analysis
Liver Diseases
Early Diagnosis
Tissue Donors
Transplants
Transplant Recipients
Infection

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Wiesner, R. H., Marin, E., Porayko, M. K., Steers, J. L., Krom, R. A. F., & Paya, C. V. (1993). Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation. Gastroenterology Clinics of North America, 22(2), 351-366.

Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation. / Wiesner, R. H.; Marin, E.; Porayko, M. K.; Steers, J. L.; Krom, R. A F; Paya, C. V.

In: Gastroenterology Clinics of North America, Vol. 22, No. 2, 1993, p. 351-366.

Research output: Contribution to journalArticle

Wiesner, RH, Marin, E, Porayko, MK, Steers, JL, Krom, RAF & Paya, CV 1993, 'Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation', Gastroenterology Clinics of North America, vol. 22, no. 2, pp. 351-366.
Wiesner, R. H. ; Marin, E. ; Porayko, M. K. ; Steers, J. L. ; Krom, R. A F ; Paya, C. V. / Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation. In: Gastroenterology Clinics of North America. 1993 ; Vol. 22, No. 2. pp. 351-366.
@article{4aa98fe6b2784f319726828fbdc49adc,
title = "Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation",
abstract = "CMV is one of the most frequent viral infections after orthotopic liver transplantation. Thus, there should be a high index of clinical suspicion, particularly in liver transplant recipients who have risk factors for the development of CMV disease, including donor CMV seropositivity, the use of antilymphocyte preparations, and retransplantation. The availability of effective antiviral therapy to treat CMV disease has emphasized the importance of an aggressive approach to the early diagnosis and treatment of this viral infection. Ganciclovir has been a major advancement in the treatment of severe CMV disease and has had a major impact on reducing the incidence and severity of CMV disease and its complications in the liver transplant recipient. Furthermore, these antiviral agents are now being evaluated for their prophylactic potential. Indeed, a number of these agents or combinations of these agents have been shown to be effective in reducing the incidence and severity of CMV disease, particularly in the CMV-seropositive transplant recipient; however, the cost-effectiveness of such therapy and its overall impact on long-term graft and patient outcome remain poorly defined at this time. Further investigations will be needed to define the role and importance of prophylactic therapy for the prevention of CMV infection and disease in the liver transplant recipient.",
author = "Wiesner, {R. H.} and E. Marin and Porayko, {M. K.} and Steers, {J. L.} and Krom, {R. A F} and Paya, {C. V.}",
year = "1993",
language = "English (US)",
volume = "22",
pages = "351--366",
journal = "Gastroenterology Clinics of North America",
issn = "0889-8553",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation

AU - Wiesner, R. H.

AU - Marin, E.

AU - Porayko, M. K.

AU - Steers, J. L.

AU - Krom, R. A F

AU - Paya, C. V.

PY - 1993

Y1 - 1993

N2 - CMV is one of the most frequent viral infections after orthotopic liver transplantation. Thus, there should be a high index of clinical suspicion, particularly in liver transplant recipients who have risk factors for the development of CMV disease, including donor CMV seropositivity, the use of antilymphocyte preparations, and retransplantation. The availability of effective antiviral therapy to treat CMV disease has emphasized the importance of an aggressive approach to the early diagnosis and treatment of this viral infection. Ganciclovir has been a major advancement in the treatment of severe CMV disease and has had a major impact on reducing the incidence and severity of CMV disease and its complications in the liver transplant recipient. Furthermore, these antiviral agents are now being evaluated for their prophylactic potential. Indeed, a number of these agents or combinations of these agents have been shown to be effective in reducing the incidence and severity of CMV disease, particularly in the CMV-seropositive transplant recipient; however, the cost-effectiveness of such therapy and its overall impact on long-term graft and patient outcome remain poorly defined at this time. Further investigations will be needed to define the role and importance of prophylactic therapy for the prevention of CMV infection and disease in the liver transplant recipient.

AB - CMV is one of the most frequent viral infections after orthotopic liver transplantation. Thus, there should be a high index of clinical suspicion, particularly in liver transplant recipients who have risk factors for the development of CMV disease, including donor CMV seropositivity, the use of antilymphocyte preparations, and retransplantation. The availability of effective antiviral therapy to treat CMV disease has emphasized the importance of an aggressive approach to the early diagnosis and treatment of this viral infection. Ganciclovir has been a major advancement in the treatment of severe CMV disease and has had a major impact on reducing the incidence and severity of CMV disease and its complications in the liver transplant recipient. Furthermore, these antiviral agents are now being evaluated for their prophylactic potential. Indeed, a number of these agents or combinations of these agents have been shown to be effective in reducing the incidence and severity of CMV disease, particularly in the CMV-seropositive transplant recipient; however, the cost-effectiveness of such therapy and its overall impact on long-term graft and patient outcome remain poorly defined at this time. Further investigations will be needed to define the role and importance of prophylactic therapy for the prevention of CMV infection and disease in the liver transplant recipient.

UR - http://www.scopus.com/inward/record.url?scp=0027152033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027152033&partnerID=8YFLogxK

M3 - Article

C2 - 8389735

AN - SCOPUS:0027152033

VL - 22

SP - 351

EP - 366

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

SN - 0889-8553

IS - 2

ER -